Resolution of the Expert Board on the development of a regional program for the early diagnosis of type 1 diabetes in children and the implementation of preventive measures among patients at risk

The prevalence of type 1 diabetes mellitus (T1DM) continues to grow, and despite the advances in insulin therapy, the optimal control of T1DM is not achieved yet. Its clinical onset is often associated with diabetic ketoacidosis, which determines a high risk of recurrent events and early development of severe complications, determining the disease burden and necessitating the development of a set of specific arrangements for early detection of preclinical stages of the disease.

On March 20, 2025, a scientific and practical conference “Pediatric and Adolescent Endocrinology: Opportunities, Challenges, and Mistakes” was held in Novosibirsk, which included an Expert Board of pediatric endocrinologists from the Siberian Federal District. The conference focused on scientific advances in the study of T1DM and implementing strategies for its early detection and monitoring in real-life endocrinologic practice. Based on the results of scientific reports and discussions held during the Expert Board meeting, experts decided on the need to implement a socially significant initiative for the timely diagnosis of T1DM before its clinical manifestation in order to prevent its onset with ketoacidosis, which significantly worsens the disease prognosis, and to reduce the risk of complications.

1. List of instructions from the President of the Russian Federation following a meeting with members of the All-Russian Public Organization “Business Russia” (approved by the President of the Russian Federation 26.04.2022 No. Pr-740). URL: https://www.consultant.ru/document/cons_doc_LAW_415917/ (accessed 20.06.2025).

2. Federal Project “Diabetes mellitus Control” URL: https://diabet.endocrincentr.ru/specialistam/federalnye_proekty (accessed 20.06.2025).

3. Type 1 diabetes mellitus in children: clinical guidelines. 2025. https://cr.minzdrav.gov.ru/preview-cr/287_3 (accessed 20.06.2025).

4. On the Federal Budget for 2025 and for the planning period of 2026 and 2027: Federal Law No. 419- FZ of 11.30.2024. URL: http://government.ru/docs/all/156651/ (accessed 20.06.2025).

5. Ziegler A.G., Rewers M., Simell O. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013 19;309(23):2473- 2479. DOI: 10.1001/jama.2013.6285.

6. Parikka V., Näntö-Salonen K., Saarinen M. et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk // Diabetologia. 2012;55(7):1926-1936. DOI: 10.1007/s00125-012-2523-3.

7. Insel R.A., Dunne J.L., Atkinson M.A. et al. Staging presymptomatic type 1 diabetes: a scientifi c statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964- 1974. DOI: 10.2337/dc15-1419.

8. Barker J.M., Goehrig S.H., Barriga K. et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404. DOI: 10.2337/diacare.27.6.1399.

9. Ehrmann D., Kulzer B., Roos T. et al. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol. 2020;8(5):436-446. DOI: 10.1016/S2213-8587(20)30042-5.

10. Primavera M., Giannini C., Chiarelli F. Prediction and prevention of type 1 diabetes. Front. Endocrinol. (Lausanne). 2020;11:248. DOI: 10.3389/fendo.2020.00248.

11. Peters A. Screening for autoantibodies in type 1 diabetes: A call to action // J. Fam. Pract. 2021;70(6S):S47- S52. DOI: 10.12788/jfp.0223.

12. So M., Speake C., Steck A.K. et al. Advances in type 1 diabetes prediction using islet autoantibodies: Beyond a simple count. Endocr. Rev. 2021;42(5):584-604. DOI: 10.1210/endrev/bnab013.

13. Ziegler A.G., Kick K., Bonifacio E. et al.; Fr1da Study Group. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-351. DOI: 10.1001/jama.2019.21565.

14. Pöllänen P.M., Ryhänen S.J., Toppari J. et al. Dynamics of islet autoantibodies during prospective follow-up from birth to age 15 years. J. Clin. Endocrinol. Metab. 2020;105(12):e4638-e4651. DOI: 10.1210/clinem/dgaa624.

15. Sims E.K., Besser R.E.J., Dayan C. et al.; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71(4):610-623. DOI: 10.2337/dbi20-0054.

16. Early diagnosis and treatment of type 1 diabetes mellitus. Issues of clinical feasibility, organization, and accessibility of medical care. Resolution on the results of the Expert Council held on December 17, 2024, Moscow. Medical Technologies. Assessment and Choice. 2025;47(2):10-17. DOI: 10.17116/ medtech20254702110. (In Russ.)

17. Gomez-Lopera N., Pineda-Trujillo N., Diaz-Valencia P.A. Correlating the global increase in type 1 diabetes incidence across age groups with national economic prosperity: A systematic review. World J. Diabetes. 2019;10(12):560-580. DOI: 10.4239/wjd.v10.i12.560.

18. Laptev D.N., Bezlepkina O.B., Sheshko E.L. et al. Main epidemiological indicators of type 1 diabetes mellitus in children in the Russian Federation for 2014–2023. Problems of Endocrinology. 2024;70(5):76-83. DOI: 10.14341/probl13515. (In Russ.)

19. Phillip M., Achenbach P., Addala A. et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731-1759. DOI: 10.1007/s00125-024-06205-5.